# US 10,869,873 B2 · Methods and compositions for treating viral diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,873 B2
- Document ID: US10869873B2
- Status: Granted
- Kind: B2
- Application number: 15/150,293
- Filed: 2016-05-09
- Published: 2017-01-05
- Granted: 2020-12-22
- Earliest claimed: 2011-12-06
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Shirit Einav; Rina Barouch-Bentov; Gregory Neveu; Amotz Zivav
- Web page: https://patentgrep.com/patent/US10869873B2

## CPC

- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- C12C 1/18: Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt (malt products for use as foodstuffs A23L)
- C12Q 1/18: Testing for antimicrobial activity of a material
- G01N 2500/10: involving cells
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12C: BEER; PREPARATION OF BEER BY FERMENTATION (ageing or ripening by storing C12H1/22; methods for reducing the alcohol content after fermentation C12H3/00; methods for increasing the alcohol content after fermentation C12H6/00; venting devices for casks, barrels or the like C12L9/00); PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides a method for treating viral infections and coinfections through the use of inhibitory agents that prevent a unique viral structural protein motifs from binding to host proteins from the clathrin adaptor proteins family and subsequently preventing viral replication.

## Claims

### Claim 1

A method of inhibiting assembly or budding of Dengue virus, comprising contacting a host cell that is infected with Dengue virus with sunitinib or a pharmaceutically acceptable salt of sunitinib, wherein the sunitinib inhibits adaptor-associated kinase 1 (AAK1), thereby inhibiting assembly or budding of the Dengue virus.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sunitinib or pharmaceutically acceptable salt of sunitinib blocks binding of a viral structural protein to a host protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein said sunitinib or pharmaceutically acceptable salt of sunitinib competes with a viral structural protein for binding to a host protein.

### Claim 4 (depends on 1)

The method of claim 1, wherein said sunitinib or pharmaceutically acceptable salt of sunitinib competes with a host protein for binding to a viral structural protein.

### Claim 5 (depends on 1)

The method of claim 1, further comprising contacting said host cell with erlotinib, midostaurin, or a pharmaceutically acceptable salt or combination thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the host cell is contacted with erlotinib or a pharmaceutically acceptable salt of erlotinib.

### Claim 7 (depends on 5)

The method of claim 5, wherein the host cell is contacted with midostaurin or a pharmaceutically acceptable salt of midostaurin.

### Claim 8 (depends on 1)

The method of claim 1, wherein assembly or budding of said Flaviviridae is inhibited.